GHRP-2 (Pralmorelin) Research Compound Profile

1. Introduction to GHRP-2

GHRP-2, also known by its research name Pralmorelin, is a synthetic hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) developed as a potent secretagogue for Growth Hormone (GH). It functions by mimicking the action of the endogenous hormone Ghrelin, primarily by binding to the Ghrelin receptor (also known as the Growth Hormone Secretagogue Receptor, or GHSR-1a). This binding action is known to lead to a significant, dose-dependent release of GH from the pituitary gland.

This document serves as a comprehensive profile for GHRP-2, outlining its mechanism of action, observed research highlights, and necessary compliance stipulations for its use strictly within a laboratory research setting.

Compound Name

Synonym(s)

Structure Type

Primary Receptor

GHRP-2

Pralmorelin

Synthetic Hexapeptide

GHSR-1a (Ghrelin Receptor)

2. Source and Mechanism of Action

Source

GHRP-2 is a Synthetic hexapeptide. It is not derived from natural sources but is engineered to maximize its binding affinity and agonistic activity at the GHSR-1a receptor.

Action

GHRP-2's primary mechanism of action is the Potent GH release via Ghrelin receptor. Upon administration in research models, the peptide travels to the pituitary gland, where it interacts with the GHSR-1a. This activation bypasses the negative feedback loop typically associated with somatostatin (GH-inhibiting hormone), resulting in a pulsatile and robust secretion of Growth Hormone.

Action Category

Specific Mechanism

Biological Effect

Endocrine

GHSR-1a Agonism

Growth Hormone Release

Pituitary

Suppression of Somatostatin

Increased GH Pulse Amplitude

3. Observed Research Highlights

Research studies involving GHRP-2 have indicated several distinct areas of activity beyond simple GH release, suggesting multifaceted applications in various biological systems.

Musculoskeletal System

Research models have demonstrated GHRP-2's potential to counteract muscle atrophy. The mechanism involves the modulation of key regulatory pathways in muscle catabolism.

GHRP-2 Blocks Atrogin-1/MuRF1 to stop muscle wasting. Atrogin-1 (also known as F-box protein 32 or FBXO32) and Muscle Ring Finger 1 (MuRF1) are E3 ubiquitin ligases that play critical roles in the Ubiquitin-Proteasome System (UPS), which is the main pathway for muscle protein degradation during conditions of wasting (e.g., cachexia, disuse atrophy). By inhibiting the expression or activity of these specific ligases, GHRP-2 is hypothesized to preserve muscle mass and function in research models subjected to catabolic stress.

Cardiovascular System

Evidence suggests a protective role for GHRP-2 in cardiac tissues, potentially linking the Ghrelin signaling pathway to heart cell viability.

The compound Protects cardiomyocytes from apoptosis. Apoptosis, or programmed cell death, is a significant contributor to damage following myocardial injury. By activating the Ghrelin receptor pathway, GHRP-2 may engage downstream anti-apoptotic signaling cascades, thereby promoting the survival of heart muscle cells under ischemic or stressful conditions.

Sleep Cycle Modulation

GHRP-2 has been observed to influence sleep architecture, which is a common finding among secretagogues acting on the Ghrelin pathway.

The peptide Enhances deep sleep (Stage 3/4) and REM. Deep sleep (Slow-Wave Sleep or SWS) is the stage where the highest endogenous GH release naturally occurs. GHRP-2 administration appears to consolidate SWS, which is beneficial for repair and recovery processes, while also positively influencing Rapid Eye Movement (REM) sleep duration and quality.

Bioavailability and Administration

An important consideration for laboratory studies is the compound's bioavailability across different routes of administration.

GHRP-2 has been found to be Active via oral, sublingual, and subcutaneous routes in research models. This broad activity profile provides flexibility in study design, allowing researchers to choose the most appropriate method for their specific model and experimental objectives.

4. Compliance and Safety Information

Research Grade and Restriction

This compound is strictly for laboratory investigation and must adhere to all regulatory guidelines.

• Grade: Laboratory Research Grade. This compound is manufactured and purified solely for research and quality control purposes. It does not meet the standards or approvals for pharmaceutical use.
• Restriction: Not for human consumption. GHRP-2 (Pralmorelin) is intended for in vitro (cell culture) or in vivo (animal model) research only. Any unauthorized use outside of a controlled laboratory environment is strictly prohibited and potentially dangerous.

Storage and Handling

For optimal stability and integrity of the compound, researchers must follow strict storage guidelines.

Parameter

Guideline

Details

Storage Temperature

Long-term: -20°C to -80°C

Store in lyophilized form

Reconstitution Solvent

Sterile Water or Bacteriostatic Water

Post-Reconstitution

Refrigerate (2°C to 8°C)

Use within 14 days or aliquot and freeze

Required Documentation

Researchers utilizing GHRP-2 are required to maintain a comprehensive record of its usage.

1. Material Safety Data Sheet (MSDS) review: File
2. Standard Operating Procedure (SOP) for handling peptides: File
3. GHRP-2 Inventory Log: File

5. Potential Research Applications

Based on the known mechanisms and observed highlights, GHRP-2 can be utilized in several distinct areas of biomedical research:

Endocrine Studies

• Investigating the regulation of the GH/IGF-1 axis.
• Studying the kinetics of GH release and its pulsatility.

Muscle Physiology

• Modeling and researching treatments for sarcopenia or cachexia.
• Understanding the regulation of the Atrogin-1/MuRF1 pathway.

Cardiology Research

• Examining anti-apoptotic signaling pathways in cardiomyocytes.
• Researching the role of the Ghrelin receptor in heart failure models.

Sleep Medicine

• Analyzing the influence of GH secretagogues on Slow-Wave Sleep (SWS).
• Investigating neuroendocrine links between metabolism and sleep architecture.

6. Responsible Disposal

All unused or expired GHRP-2 solution and contaminated waste (e.g., syringes, gloves, glassware) must be disposed of according to institutional biohazard and chemical waste protocols at Place. Never dispose of research compounds in standard trash or down any drain. Researchers should consult the waste disposal guidelines provided in the laboratory's safety manual File.

7. Future Directions in GHRP-2 Research

Ongoing research continues to explore the ancillary effects of GHRP-2. Potential areas for further study include:

• Metabolic Effects: Evaluation of GHRP-2's impact on insulin sensitivity and lipid metabolism, independent of GH release.
• Neuroprotection: Investigating its potential role in mitigating neuronal damage or promoting recovery in models of neurodegenerative disease.
• Immune Modulation: Assessing the Ghrelin-GHRP-2 axis's influence on inflammatory responses.

For detailed protocols, please attend the mandatory compliance briefing scheduled for Date at Calendar event.